Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04477200
Recruitment Status : Recruiting
First Posted : July 20, 2020
Last Update Posted : January 26, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Tracking Information
First Submitted Date  ICMJE July 14, 2020
First Posted Date  ICMJE July 20, 2020
Last Update Posted Date January 26, 2022
Actual Study Start Date  ICMJE August 5, 2020
Estimated Primary Completion Date October 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 10, 2022)
  • Concentration of mycophenolic acid (MPA) in tumor tissue in Phase 0 participants [ Time Frame: At 1 week ]
    The concentration of MPA (the active metabolite of mycophenolate mofetil [MMF]) in tumor tissue, measured by mass spectrometry on a continuous scale after one week of MMF administration. This measure includes all phase 0 participants.
  • Number of recurrent phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level [ Time Frame: Up to 28 days following completion of MMF + RT (up to ~9 weeks) ]
    DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced from the start of treatment with MMF and for up to 4 weeks after completion of MMF + radiation therapy (RT). Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. This measure includes only phase 1 participants with recurrent GBM/GS.
  • Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT1 period [ Time Frame: Up to 28 days following completion of MMF + RT + TMZ (up to ~11 weeks) ]
    DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced from the start of treatment with MMF and for up to 4 weeks after completion of MMF + RT + TMZ. Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. This measure includes only newly diagnosed phase 1 participants.
  • Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT2 period [ Time Frame: During the first 2 cycles (8 weeks) of MMF with adjuvant TMZ (up to ~19 weeks) ]
    DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced during the first 2 cycles (8 weeks) of MMF with adjuvant TMZ. (The first cycle of MMF with adjuvant TMZ begins 28 days post-RT.) These will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. This measure includes only newly diagnosed phase 1 participants.
Original Primary Outcome Measures  ICMJE
 (submitted: July 14, 2020)
  • Phase 0: Concentration of mycophenolic acid (MPA) in tumor tissue [ Time Frame: After one week of MMF administration ]
    The concentration of MPA (the active metabolite of mycophenolate mofetil [MMF]) in tumor tissue, measured by mass spectrometry on a continuous scale.
  • Phase 1: Number of participants who experience dose-limiting toxicities (DLTs) at each dose level [ Time Frame: Up to 28 days following completion of radiation and MMF ]
    DLT defined per protocol and assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 10, 2022)
  • Concentrations of guanosine triphosphate (GTP) in tumor tissue in Phase 0 participants [ Time Frame: After one week of MMF administration ]
    The concentrations of GTP in tumor tissue, measured by mass spectrometry on a continuous scale. This measure includes all phase 0 participants.
  • Adverse events associated with treatment in all Phase 1 Participants [ Time Frame: Up to 28 days following completion of MMF + RT (up to ~9 weeks) ]
    Toxicities at each dose level will be tabulated, categorized by grade and attribution. This measure includes all phase 1 participants.
  • Adverse events associated with treatment in newly diagnosed phase 1 participants [ Time Frame: Up to 28 days following completion of MMF with adjuvant temozolomide (up to ~15 months) ]
    Toxicities at each dose level will be tabulated, categorized by grade and attribution. This measure includes only newly diagnosed phase 1 participants.
  • Overall Response Rate in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    Determined by modified Response Assessment for Neuro-Oncology (mRANO) criteria. The number and proportion of patients with progressive disease, stable disease, partial and complete response will be calculated for each dose level and overall. This measure includes only phase 1 participants with recurrent GBM/GS.
  • Median Progression Free Survival (PFS) in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    PFS defined as time from date of registration to the date of documented progressive disease, other disease related therapy or death. Determined by mRANO criteria. This measure includes only phase 1 participants with recurrent GBM/GS.
  • Median Freedom from Local Progression (FFLP) in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    FFLP defined as time from date of registration to the date of documented local progressive disease. Determined by mRANO criteria. This measure includes only phase 1 participants with recurrent GBM/GS.
  • Median Overall Survival (OS) in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    OS defined as time from date of registration to date of death or last follow up. Determined by Kaplan Meier method. This measure includes only phase 1 participants with recurrent GBM/GS.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 14, 2020)
  • Phase 0: Concentrations of guanosine triphosphate (GTP) in tumor tissue [ Time Frame: After one week of MMF administration ]
    The concentrations of GTP in tumor tissue, measured by mass spectrometry on a continuous scale.
  • Phase 0: Concentrations of guanosine triphosphate (GTP) in plasma [ Time Frame: After one week of MMF administration ]
    The concentrations of GTP in plasma, measured by mass spectrometry on a continuous scale.
  • Phase 1: Adverse events associated with MMF + re-irradiation [ Time Frame: Up to 28 days following completion of radiation and MMF ]
    Toxicities at each dose level will be tabulated, categorized by grade and attribution.
  • Phase 1: Overall Response Rate [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    Determined by standard Response Assessment for Neuro-Oncology (RANO) criteria. The number and proportion of patients wtih progressive disease, stable disease, partial and complete response will be calculated for each dose level and overall.
  • Phase 1: Median Progression Free Survival (PFS) [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    PFS defined as time from date of registration to the date of documented progressive disease, other disease related therapy or death. Determined by standard RANO criteria
  • Phase 1: Median Freedom from Local Progression (FFLP) [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    FFLP defined as time from date of registration to the date of documented local progressive disease. Determined by standard RANO criteria
  • Phase 1: Median Overall Survival (OS) [ Time Frame: Until study stops or death; up to approximately 3 years. ]
    OS defined as time from date of registration to date of death or last follow up.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
Official Title  ICMJE Phase 0/I Dose Escalation Study of Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
Brief Summary This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
Detailed Description The goal of the Phase 0 component is to determine if MMF achieves active concentrations in brain tumors. Eight participants in Phase 0 will receive MMF for one week before undergoing an already planned biopsy or re-resection (surgical removal) of glioblastoma or gliosarcoma (GBM/GS). A small portion of the tumor, removed as part of clinical care, will be used for testing in this study. Sixty additional participants will be enrolled in the Phase 1 component of the trial (30 with recurrent GBM/GS and 30 with newly diagnosed GBM/GS). The goal of the Phase 1 component is to find the dose of MMF that works best without causing severe side effects (the maximum tolerated dose) when combined with radiation in recurrent GBM/GS and with radiation and chemotherapy in newly diagnosed GBM/GS. Participants in Phase 0 who meet the eligibility criteria for the Phase 1 component may participate in both phases.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Phase 0 will include 8 participants; eligible participants from phase 0 may continue on to phase 1.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Glioblastoma
  • Gliosarcoma
Intervention  ICMJE
  • Drug: Mycophenolate Mofetil
    500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
    Other Name: MMF
  • Radiation: Radiation Therapy
    40.5 Gy in 15 fractions
    Other Name: RT
  • Procedure: Re-resection (as part of standard of care)
    Re-resection or biopsy of tumor as part of standard of care
  • Drug: Temozolomide
    Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
    Other Name: TMZ
  • Drug: Mycophenolate Mofetil
    250-2000mg orally twice daily, one week prior to and concurrent with RT.
    Other Name: MMF
  • Drug: Mycophenolate Mofetil
    250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
    Other Name: MMF
  • Radiation: Radiation Therapy
    60 Gy in 30 fractions
    Other Name: RT
Study Arms  ICMJE
  • Experimental: Phase 0 - Recurrent glioblastoma (GBM) / gliosarcoma (GS)
    Mycophenolate mofetil
    Interventions:
    • Drug: Mycophenolate Mofetil
    • Procedure: Re-resection (as part of standard of care)
  • Experimental: Phase 1 - Recurrent GBM / GS
    Mycophenolate mofetil; radiation therapy
    Interventions:
    • Radiation: Radiation Therapy
    • Drug: Mycophenolate Mofetil
  • Experimental: Phase 1 - Newly Diagnosed GBM / GS
    Mycophenolate mofetil; radiation therapy; temozolomide
    Interventions:
    • Drug: Temozolomide
    • Drug: Mycophenolate Mofetil
    • Radiation: Radiation Therapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 10, 2022)
68
Original Estimated Enrollment  ICMJE
 (submitted: July 14, 2020)
38
Estimated Study Completion Date  ICMJE October 2027
Estimated Primary Completion Date October 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Glioblastoma or gliosarcoma (recurrent or newly diagnosed).
  • Karnofsky Performance Status 60 or greater.
  • Phase 0: Candidate for clinically indicated re-resection or biopsy of glioblastoma or gliosarcoma per treating physician(s).
  • Phase 1, Recurrent: Candidate for clinically indicated re-irradiation of glioblastoma or gliosarcoma per treating physician(s) (No more than one prior course of radiation for GBM).
  • Phase 1, Newly Diagnosed: Candidate for upfront standard of care chemoradiation for glioblastoma or gliosarcoma per treating physician(s), to start no earlier than 14 days post- operatively from last definitive surgery for glioblastoma or gliosarcoma (if more than one surgery done. Ex. biopsy prior to resection).
  • ANC >=1,500 cells/mm^3 within 14 days prior to enrollment.
  • Patient (men and childbearing age women) agrees to the use of highly effective contraception during study participation and for at least 6 weeks for female patients and 90 days for male patients after final MMF administration.
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  • Lack of histopathological diagnosis of the tumor.
  • Gliomatosis cerebri pattern (tumor involving 3 or more lobes) of disease.
  • Leptomeningeal disease.
  • Use of bevacizumab within 8 weeks of study enrollment.
  • Known history of HIV.
  • Active hepatitis B or C infection.
  • Active systemic or central nervous system (CNS) infection.
  • Grade 4 lymphopenia (if ALC <0.5, patient must be on Pneumocystis jirovecii prophylaxis).
  • Estimated CrCl < 25 ml/min.
  • History of organ transplantation.
  • Patients with known hypoxanthine-guanine phosphoribosyl-transferase deficiency.
  • Serious intercurrent disease.
  • History of allergic reaction or hypersensitivity to mycophenolate mofetil or mycophenolic acid or any component of the drug product; or medical contraindication for MMF per treating physician(s).
  • Known immunosuppressive condition from autoimmune disease, immune deficiency syndrome, or chronic immunosuppressive therapy.
  • Inability to undergo MRI brain with and without contrast.
  • Pregnant or lactating women.
  • Patients with known phenylketonuria.
  • Phase 0: Patients undergoing biopsy who are deemed unlikely to have sufficient tissue to spare for research purposes (e.g., those whose tumors are in an eloquent brain location where all tissue taken must be used for diagnostic purposes).
  • Phase I: Increase in steroid requirement within 7 days of study enrollment (stable or decreasing dose allowed).
  • Phase I, Recurrent: Radiation within 6 months prior to study enrollment.
  • Phase I, Recurrent: Surgery within 4 weeks of re-irradiation.
  • Phase I, Newly Diagnosed: History of hypersensitivity reactions to temozolomide or any other ingredients in temozolomide and dacarbazine.
  • Phase I, Newly Diagnosed: Prior chemotherapy or radiation therapy for glioblastoma or gliosarcoma.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04477200
Other Study ID Numbers  ICMJE UMCC 2019.192
HUM00175785 ( Other Identifier: University of Michigan )
R37CA258346 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University of Michigan Rogel Cancer Center
Study Sponsor  ICMJE University of Michigan Rogel Cancer Center
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Yoshie Umemura, MD University of Michigan Rogel Cancer Center
PRS Account University of Michigan Rogel Cancer Center
Verification Date January 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP